RDX227675

Phase 2Small molecule

AArdelyx

RDX227675 is one of 9 small molecule programs targeting Hyperkalemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperkalemiaActive, not recruiting

HyperkalemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Hyperkalemia

#DrugCompanyPhaseTrials

Salbutamol

GSK

Approved

2 2

Insulin 320

Novo Nordisk

Approved

1 3

Veltassa

VVifor Pharma

Phase 3

6 4

Sodium Valproate

AstraZeneca

Phase 3

8 5

Insulin Regular

TThe University of Texas Medical Branch, Galveston

Approved

1 6

Zirconium Silicate (ZS)

ZZS Pharma, Inc.

Phase 3

1 7

WS016

WWaterstone Pharmaceutical (Wuhan) Co., LTD.

Phase 2

2 8

RDX227675

AArdelyx

Phase 2

1 9

Sodium Polystyrene Sulfonate

ZZS Pharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperkalemia1 trial

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Terminated·AArdelyx·Phase 2·NCT03018067·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RDX227675. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RDX227675 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RDX227675. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ardelyx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArdelyx

RDX227675

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperkalemia1 trial

References

Drug Info

Quick Facts

Related News